 phase trial recombinant human beta combination myelosuppressive doses patients gastrointestinal cancer doses recombinant human beta beta myelosuppressive dose patients gastrointestinal cancer Transient neutropenia monocytopenia lymphocytopenia mean dose-dependent neutrophil leukocytosis days beta administration platelet counts median days range beta administration Transient hypoglycemia rebound hyperglycemia elevations serum cortisol C-reactive protein Side effects fever rigors headache majority patients Hypotension patients dose level micrograms/kg days neutropenia plus beta alone difference statistical significance data beta stimulatory effects human hematopoiesis